By Denny Jacob
Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer.
Shares were trading around $25.22. The stock is up 34% on the year.
The oncology company and Zai Lab, a biopharmaceutical company, said a Phase 3 trial met its primary endpoint and demonstrated a statistically significant improvement in medical overall survival versus a control. The trial evaluated the use of tumor treating fields therapy concomitantly with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Novocure said it plans to file for regulatory approval of the treatment and plans to submit the trial results for presentation at an upcoming medical congress. Zai Lab plans to file for regulatory approval in China.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 02, 2024 07:41 ET (12:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.